Richard Daniell, Executive VP European Commercial at Teva Pharmaceutical Industries Ltd, filed a Form 144 notice on November 11, 2026, proposing the sale of 20,003 ordinary shares acquired through a stock option exercise and sale on the same date.

Key Highlights

  • Seller: Daniell Richard, identified as an officer with the title Executive VP European Commercial at Teva Pharmaceutical Industries Ltd.
  • Shares proposed for sale: 20,003 ordinary shares, with an aggregate market value of $856,154.84, based on an indicative market price of $42.801322 per share.
  • Acquisition method: The shares were acquired on November 11, 2026, through a stock option exercise and sale, with Teva Pharmaceutical Industries Limited named as the person from whom acquired.
  • Broker: Citigroup Global Markets Inc., 390 Greenwich Street, New York, NY 10013, is named as the executing broker.
  • Prior sales: Daniell Richard also sold 25,000 ordinary shares on November 9, 2026, with gross proceeds of $1,072,789.40, disclosed as sales during the past three months.
  • Shares outstanding: The filing states approximately 1,166,826,784 ordinary shares outstanding, per the remarks noting figures are based on ordinary shares.
  • Exchange: The ordinary shares are listed on NYSE:TEVA, as identified in the filing.

Daniell Richard's Proposed Option Exercise Sale of Teva Ordinary Shares

According to the Form 144 filing dated November 11, 2026, Daniell Richard, an officer of Teva Pharmaceutical Industries Ltd holding the role of Executive VP European Commercial, provided notice of a proposed sale of 20,003 ordinary shares. The filing identifies the nature of the acquisition transaction as a "stock option exercise and sale," with both the acquisition date and the approximate date of sale listed as November 11, 2026. Payment is characterized as "compensation" in the filing.

The filing reports an aggregate market value of $856,154.84 for the 20,003 shares proposed for sale. The remarks section of the filing states that the shares outstanding figure and market value are "based on ordinary shares" and that the per-share indicative market price used is $42.801322. Total ordinary shares outstanding are listed as 1,166,826,784. The proposed sale is to be executed through Citigroup Global Markets Inc. on the NYSE.

In the section covering securities sold during the past three months, the filing discloses that Daniell Richard sold 25,000 ordinary shares on November 9, 2026, with gross proceeds of $1,072,789.40. The filing was submitted as a live filing with a filer CIK of 0001726096. The Form 144 notice states that the seller represents, by signing, that he does not know of any material adverse information regarding the issuer's current and prospective operations that has not been publicly disclosed.

What Was Disclosed

Teva Pharmaceutical officer Daniell Richard filed a Form 144 notice proposing the sale of 20,003 ordinary shares, acquired via stock option exercise on November 11, 2026, with an aggregate market value of $856,154.84. A prior sale of 25,000 shares on November 9, 2026, was also disclosed.